Wholly Owned Pipeline

PureTech's Wholly Owned Programs are designed to enhance on-target efficacy, enable oral administration or improve tolerability to unlock new classes of medicine that have been held back by one of these issues.

Wholly Owned Pipeline

Our programs1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Idiopathic pulmonary fibrosis (IPF)

2

IPF

~3M worldwide


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). We are also exploring the potential evaluation of LYT-100 in radiation induced fibrosis, myocardial and other organ system fibrosis based on the strength of existing clinical data around the use of pirfenidone in these indications.

LYT-100
Deupirfenidone
Exploring additional indications (e.g., myocardial and other organ system fibrosis, radiation induced fibrosis, lymphedema)

1

Exploring additional indications (e.g., myocardial and other organ system fibrosis, radiation induced fibrosis, lymphedema)

Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). We are also exploring the potential evaluation of LYT-100 in myocardial and other organ system fibrosis, radiation induced fibrosis and lymphedema based on the strength of existing clinical data around the use of pirfenidone in these indications.

LYT-200
Anti-Galectin-9 MAb
Solid tumors

1

Solid tumors

>32K/year U.S. (Metastatic pancreatic cancer)
>33K/year U.S. (Metastatic CRC)
>4K/year U.S. (Metastatic cholangiocarcinoma)


Fully human monoclonal antibody designed to inhibit the activity of galectin-9, a key molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells, which we are developing for difficult-to-treat cancer indications with poor survival rates, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA).

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

>32K/year U.S. (Metastatic pancreatic cancer)
>33K/year U.S. (Metastatic CRC)
>4K/year U.S. (Metastatic cholangiocarcinoma)


Fully human IgG1 monoclonal antibody directed against the delta-1 chain of T cells bearing gamma delta-1 T cell receptors that we have designed to target and deplete immunosuppressive gamma delta-1 T cells in cancer.

LYT-300
Oral Allopregnanolone
Neurological and neuropsychological conditions

1

Neurological and neuropsychological conditions

Designed to unlock the validated efficacy of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need. Allopregnanolone, a positive allosteric modulator of GABAA receptors, has therapeutic potential across a wide range of neurological conditions like depression, epilepsy and other neurological and neuropsychological conditions, but has poor oral bioavailability as a result of first-pass liver metabolism. An intravenous formulation of allopregnanolone is approved by the FDA as a 60-hour infusion for the treatment of post-partum depression, though the method of administration has significant limitations.

LYT-510
Oral Immunosuppressant
IBD/chronic pouchitis

Preclinical

Inflammatory bowel disease and chronic pouchitis

~3.9M U.S.


Oral inflammation-targeting formulation of tacrolimus, a potent immunosuppressant drug, in development for the potential treatment of inflammatory bowel disease (IBD) and chronic pouchitis. Tacrolimus is approved for certain indications, however its approval for IBD and chronic pouchitis has been hampered by systemic toxicities, narrow therapeutic window of activity and opportunistic infections that can arise from systemic immunosuppression. There is clinical data demonstrating that tacrolimus is effective in addressing IBD indications, but adverse events have held it back.

LYT-500
Oral IL-22 +
Immunosuppressant
IBD

Preclinical

Inflammatory bowel disease

~3.9M U.S.

Therapeutic candidate being advanced for the potential treatment of inflammatory bowel disease (IBD) that is designed with a dual mechanism of action to provide both mucosal repair and targeted resolution of tissue inflammation.
LYT-503/IMB-150
(Partnered program)
Non-opioid
IC/BPS

Preclinical

Interstitial cystitis/bladder pain syndrome

~4-12M U.S.


Therapeutic candidate being advanced as a partnered program for the potential treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) that is designed to selectively treat inflamed tissues along the bladder wall while minimizing the potential for drug-related side effects in healthy parts of the body.

Phase completedPhase in progress

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.

Developing breakthrough medicines at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out